Therapeuticsmd, INC. (TXMD) — SEC Filings

Overview

Therapeuticsmd, INC. (TXMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: TherapeuticsMD, Inc. (TXMD) has fully transitioned into a pharmaceutical royalty company by December 31, 2025, following the December 2022 Mayne Transaction. This strategic shift involved licensing its key products, IMVEXXY, BIJUVA, and prescription prenatal vitamins, to Mayne Pharma LLC for commerc

Sentiment Summary

Across 19 filings, the sentiment breakdown is: 2 bearish, 15 neutral, 2 mixed. The dominant filing sentiment for Therapeuticsmd, INC. is neutral.

Filing Type Overview

Therapeuticsmd, INC. (TXMD) has filed 3 10-K, 5 8-K, 6 10-Q, 2 DEF 14A, 2 10-K/A, 1 SC 13G with the SEC between Mar 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (19)

• TherapeuticsMD Shifts to Royalty Model, Faces Mayne Pharma Lawsuits — 10-K · Mar 30, 2026 Risk: high
  TherapeuticsMD, Inc. (TXMD) has fully transitioned into a pharmaceutical royalty company by December 31, 2025, following the December 2022 Mayne Transaction. Th
• TherapeuticsMD Files 8-K on Shareholder Vote Matters — 8-K · Dec 16, 2025 Risk: low
  On December 15, 2025, TherapeuticsMD, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing indicates that th
• TherapeuticsMD Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  On November 12, 2025, TherapeuticsMD, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also includes Regulation FD d
• TXMD Swings to Profit Amid Royalty Model Shift, Mayne Lawsuit Looms — 10-Q · Nov 12, 2025 Risk: high
  TherapeuticsMD, Inc. (TXMD) reported a net income of $152 thousand for the three months ended September 30, 2025, a significant improvement from a net loss of $
• TherapeuticsMD Seeks 1,900% Share Increase, Board Re-election — DEF 14A · Nov 3, 2025 Risk: high
  TherapeuticsMD, Inc. (TXMD) is holding its Annual Meeting of Stockholders on December 15, 2025, to address several key proposals. Shareholders will vote on the
• TherapeuticsMD Swings to Profit Amid Royalty Model Shift, Legal Woes Persist — 10-Q · Aug 12, 2025 Risk: high
  TherapeuticsMD, Inc. (TXMD) reported a net income of $551 thousand for the three months ended June 30, 2025, a significant improvement from a net loss of $1.090
• TherapeuticsMD Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
  TherapeuticsMD, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, formerly known as AMHN, Inc., is incorporated in
• TherapeuticsMD Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: medium
  TherapeuticsMD, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on April 30, 2025, prov
• TherapeuticsMD Files 8-K: Other Events — 8-K · Apr 9, 2025 Risk: low
  On April 8, 2025, TherapeuticsMD, Inc. filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material agr
• TherapeuticsMD Files 2024 Annual Report — 10-K · Mar 27, 2025 Risk: medium
  TherapeuticsMD, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Nevada, operates in the pharmaceutical pr
• TherapeuticsMD Files 8-K on Security Holder Vote Matters — 8-K · Dec 5, 2024 Risk: low
  On December 5, 2024, TherapeuticsMD, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Neva
• SC 13G Filing — SC 13G · Nov 12, 2024
• TherapeuticsMD Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: low
  TherapeuticsMD, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as AMHN, Inc., is incorporated in Nevada and operates
• TherapeuticsMD Files Definitive Proxy Statement — DEF 14A · Oct 25, 2024 Risk: low
  TherapeuticsMD, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 25, 2024, for its fiscal year ending December 31, 2024. The filing, which is a prox
• TherapeuticsMD Files 8-K on Shareholder Nominations — 8-K · Sep 20, 2024 Risk: medium
  On September 20, 2024, TherapeuticsMD, Inc. filed an 8-K report detailing shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing does not cont
• TherapeuticsMD Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: low
  TherapeuticsMD, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, formerly known as AMHN, Inc., is incorporated in Nevada and opera
• TherapeuticsMD, Inc. Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  TherapeuticsMD, Inc. (TXMD) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. TherapeuticsMD, Inc. filed a 10-Q report for the quarterly period ende
• TherapeuticsMD, Inc. Files Amendment No. 1 to Annual Report on Form 10-K — 10-K/A · Apr 29, 2024 Risk: low
  TherapeuticsMD, Inc. (TXMD) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. TherapeuticsMD, Inc. filed an amendment (10-K/A) to its annua
• TherapeuticsMD, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: low
  TherapeuticsMD, Inc. (TXMD) filed a Annual Report (10-K) with the SEC on March 29, 2024. TherapeuticsMD, Inc. filed its annual report on Form 10-K for the fisca

Related Companies

MYX.AX

Frequently Asked Questions